BioSpace News Archive

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19

Cyteir Therapeutics, Inc. announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference, being held virtually on September 10, 2021, at 11:45am ET.

Xeris Pharmaceuticals, Inc. today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatment of hypothyroidism.

Science 37 ® Appoints Christine Pellizzari as Chief Legal Officer

cPharmaceuticals Inc. today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021

Daré Bioscience, Inc. today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data at the European Menopause and Andropause Society’s (EMAS) 13th European Congress on Menopause and Andropause being held virtually September 8 - 10, 2021.

Morphic Therapeutic today announced participation in the following investor conferences: Dr. Praveen Tipirneni, M.D., President and CEO, and Marc Schegerin, M.D., COO and CFO, are scheduled to take part in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 12:30 p.m.

Innovative Cellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company’s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART

Nemaura Medical, Inc. announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 – 15, 2021.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in September: